Ariad Pharmaceuticals' stock rose 16 percent yesterday after the company announced that the Food and Drug Administration had approved revised prescribing information and other steps the FDA required to allow Ariad to resume marketing and distribution of its leukemia drug, Iclusig.
Commercial distribution of the drug is expected to begin by mid- to late-January after the Cambridge company agreed to change Iclusig's label to include new warnings about the risks of blood clots and heart failure, and to revise recommendations about dosage and administration of the drug.
"We are committed to ... helping patients and their physicians make informed decisions about the most appropriate use of Iclusig in the context of the revised product label," said Dr. Frank Haluska, Ariad's senior vice president and chief medical officer.
At the FDA's request, the company agreed on Oct. 31 to voluntarily suspend marketing of the drug because of concerns that patients taking it could suffer life-threatening blood clots.
Anda sedang membaca artikel tentang
Ariad’s stock soars after drug approved by FDA
Dengan url
http://sedangapasaja.blogspot.com/2013/12/ariadas-stock-soars-after-drug-approved.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Ariad’s stock soars after drug approved by FDA
namun jangan lupa untuk meletakkan link
Ariad’s stock soars after drug approved by FDA
sebagai sumbernya
0 komentar:
Posting Komentar